대한뉴팜

Daehan Nupharm recorded cumulative sales of KRW 151.2 billion and operating profit of KRW 14.9 billion for the third quarter of 2024.Net profit for the same period reached KRW 12.8 billion. For the third quarter alone, the company posted sales of KRW 48.8 billion and operating profit of KRW 4.0 billion, continuing its strong financial performance. This growth was largely driven by solid sales in its core pharmaceutical business and the successful launch of its new gastroesophageal reflux disease (GERD) treatment,"Rapiduo".Rapiduo is the first and only combination therapy in Korea that pairs rabeprazole with magnesium oxide in a dual-core PPI formulation designed to improve quality of life for GERD patients. The outer layer of magnesium oxide rapidly neutralizes gastric acid and increases pH levels, protecting the inner core of rabeprazole from acid degradation and enabling effective release in the stomach. The product reaches peak plasma concentration within one hour and features reduced tablet size through dual-core technology, enhancing patient convenience. To accelerate market penetration and strengthen product awareness, Daehan Nupharm has been actively organizing medical symposiums. The “Double Protection DUO” symposium series, held three times this month, focuses on Lapiduo’s clinical value. On October 20, a session will feature Professor Ji-Won Kim (Boramae Medical Center) as chair, with lectures by Professor Jung-Won Jeon (Kyung Hee University Hospital at Gangdong) and Dr. Joong-Won Yoon (Samsung Top Internal Medicine Clinic) covering topics such as “Pharmacotherapy for Peptic Ulcers” and “Best Practices for PPI Prescribing in Primary Care.” In addition, the company continues to host its “Obesity & Wellness Injection Symposium” series, launched last year to share medical knowledge in the weight management and wellness field. Starting in Busan, followed by Seoul and Gyeongju, these events serve as key platforms to highlight Daehan Nupharm’s expertise and expand its presence in the market.

Daehan Nupharm recorded KRW 102.4 billion in sales, KRW 10.8 billion in operating profit, and KRW 10.8 billion in net profit for the second quarter of 2024, continuing its solid profitability trend. The strong performance was largely driven by stable growth in the company’s core pharmaceutical business, particularly the successful launch of its gastroesophageal reflux disease (GERD) treatment, Rapiduo Tab. Actively promoted since its release, Rapiduo Tab. combines rabeprazole (PPI) with magnesium oxide, achieving peak plasma concentration within one hour, significantly faster than existing PPI formulations (6~7 hours), thereby overcoming a key limitation of conventional products.In parallel with its commercial success, Daehan Nupharm is expanding its R&D pipeline through specialized research organizations, including the Central Research Institute for human pharmaceuticals, the Biotech Research Institute for biopharmaceuticals, and the Animal Health Research Institute for veterinary medicines.The Central Research Institute plans to add a high-dose 20/350 mg formulation of Rapiduo Tab., while also conducting active research on improved combination drugs for hypertension, hyperlipidemia, and obesity. The Biotech Research Institute is working with domestic biotech companies and overseas research institutes to develop antiviral therapies. Meanwhile, the Animal Health Research Institute has achieved notable milestones, including the 2023 launch of Teramin Tab. (terbinafine) and the world’s first fluconazole formulation for companion dogs, DH Fuzole Tab., launched in June 2024, following earlier development of the human formulation, Fuzole Tab. Beyond R&D investment, Daehan Nupharm is constructing a new GMP production facility to enhance its manufacturing capacity. The new plant will be equipped with state-of-the-art production systems to ensure the large-scale supply of high-quality pharmaceuticals.

Daehan Nupharm has announced the launch of two new veterinary medicines under its exclusive animal hospital brand, DiAange‘DH Fuzole Tab.’, the world’s first fluconazole formulation developed specifically for dogs ‘PROCOX Tab.’, an NSAID (non-steroidal anti-inflammatory drug) containing firocoxib. DH Fuzole Tab. is an antifungal treatment for Malassezia dermatitis, one of the most common dermatological conditions in companion dogs. Skin disorders account for a significant portion of veterinary consultations, and antifungal agents make up a large share of prescribed medications in this field. While human antifungal drugs such as itraconazole, fluconazole, and terbinafine are widely used, there has been a lack of verified animal-specific antifungal formulations, leading veterinarians to rely on human medicines. To address this unmet need, Daehan Nupharm has been actively developing veterinary antifungal products to provide veterinarians with more tailored treatment options. Following the 2023 launch of Teramin Tab. (terbinafine) and several years of development since 2019 based on the human formulation Fuzole Tab., the company has now achieved a global milestone, securing regulatory approval for the world’s first fluconazole formulation for dogs. The newly introduced PROCOX Tab., formulated with firocoxib, offers fast and potent pain relief with high COX-2ivity and minimal COX-1 inhibition. Thisive action reduces the risk of gastrointestinal side effects commonly associated with non-selective NSAIDs. As companion dogs live longer and chronic conditions become more prevalent, the market for veterinary NSAIDs (e.g., meloxicam, carprofen, firocoxib) continues to expand annually. Currently, the domestic market relies heavily on imported products from global pharmaceutical companies. The launch of PROCOX Tab. is expected to enhance treatment accessibility and cost efficiency through local manufacturing while broadening therapeutic options for veterinarians. Daehan Nupharm is committed to transitioning human drugs into veterinary formulations to ensure safer and more effective treatments for animals. The company plans to obtain regulatory approval for three additional veterinary products and file an IND (Investigational New Drug) application for one new compound within this year.

Daehan Nupharm held a groundbreaking and safety prayer ceremony on October 17 for the construction of a new GMP production facility at its Hyangnam plant site, marking a major step toward strengthening its global manufacturing competitiveness. The new facility will involve an investment of KRW 42.9 billion and will cover a total floor area of 15,123 m², consisting of one basement level and five above-ground floors. Construction is scheduled to take 15 months, followed by a validation period, with full-scale production beginning in 2027. This initiative is part of the company’s long-term strategy to build future growth engines. In 2021, Daehan Nupharm opened its Industry-Academia-Research Center to enhance R&D capabilities. Since 2022, the company has strategically advanced the “Hyangnam Project 1·2·3.” Phase 1: Completion of the R&D center in May 2023. Phase 2: Groundbreaking of the new GMP plant, following concept design and detailed engineering. Phase 3: Planned construction of an automated logistics warehouse. The new plant will be equipped with state-of-the-art injection and solid dosage production lines, as well as storage facilities. The injection area will include two vial lines, a lyophilization line, and an ampoule line that incorporate CIP/SIP systems and PUPSIT to ensure aseptic manufacturing. The solid dosage area will feature a BIN system to minimize contamination, with a production capacity of up to 800 million tablets annually. Korea has strengthened its pharmaceutical quality and export competitiveness since joining the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2014. In December 2023, the Ministry of Food and Drug Safety (MFDS) revised its GMP regulations to mandate contamination control strategies for sterile products. The construction of Daehan Nupharm’s new plant fully complies with these global regulatory standards, positioning the company to further enhance its export capabilities. As the largest investment in the company’s history, this new facility has been carefully planned from the design stage to optimize operational efficiency. Beyond increasing production capacity, Daehan Nupharm aims to secure a stable supply of high-quality pharmaceuticals, expand global exports, and advance R&D initiatives—paving the way to become a leading global pharmaceutical and biotech company.

Daehan Nupharm recorded KRW 48.3 billion in sales, KRW 4.5 billion in operating profit, and KRW 5.2 billion in net profit for the first quarter of 2024. Following last year’s record-high annual sales of KRW 204.2 billion, the company achieved solid performance driven by strong sales in its core pharmaceutical business. In particular, the newly launched Rapiduo Tab. and well-being injection products have contributed significantly to sales growth. Rapiduo Tab., launched in March, is a treatment for gastroesophageal reflux disease (GERD). It is an improved new drug that combines rabeprazole (PPI) and magnesium oxide, a first-of-its-kind formulation, which reaches maximum plasma concentration within one hour after administration, overcoming the limitation of existing PPI formulations that take 6 to 7 hours to take effect. To expand its growth base, the company is further strengthening R&D efforts across its business divisions, including pharmaceuticals, veterinary medicine, biotechnology, and health functional foods. In addition to Rapiduo Tab., active research is underway on improved combination drugs for hypertension, hyperlipidemia, and obesity. In the veterinary medicine sector, the company is developing various products for both livestock and companion animals. Recently, Daehan Nupharm received regulatory approval for DH Fuzole Tab., a fluconazole-based treatment specifically for Malassezia dermatitis in companion dogs. The company is also pursuing the construction of a new production facility to support future growth. In addition to investing in R&D, Daehan Nupharm plans to ensure a stable supply of high-quality pharmaceuticals through the new plant, establishing a solid foundation to further increase sales in human pharmaceuticals.

Daehan Nupharm recorded KRW 204.2 billion in annual sales for 2023, achieving its highest sales performance to date, along with KRW 18.8 billion in operating profit and KRW 12.5 billion in net profit. The company continues to focus on product research and development across its key business divisions—pharmaceuticals, veterinary medicine, biotechnology, and health functional foods. In addition to the recently launched Rapiduo Tab., R&D efforts are actively underway for improved combination drugs for hypertension, hyperlipidemia, and obesity treatment.In the veterinary medicine division, Daehan Nupharm is expanding its portfolio to cover a wide range of products for both livestock and companion animals. Notably, the company recently received regulatory approval for DH Fuzole Tab., a fluconazole-based treatment for Malassezia dermatitis in dogs. Currently, most antifungal agents prescribed in domestic animal hospitals are human medications. Although fungal skin diseases, including Malassezia infections, are common in companion animals, there has been a lack of approved veterinary drugs, highlighting the need for safe and effective animal-specific antifungal treatments. Daehan Nupharm plans to continuously introduce new products that meet veterinarians’ clinical needs. Through ongoing research and development, the company has successfully developed DH Fuzole Tab. as a veterinary medicine based on its existing human formulation. By pursuing R&D strategies that create synergy across business divisions, Daehan Nupharm aims to launch innovative products and maintain sustainable growth.

Daehan Nupharm’s health functional food brand “DiNU” has launched a new inner beauty product, “DiNU Core Collagen.”Unlike conventional collagen products made from tilapia, pangasius, or other freshwater fish scales and skin, DiNU Core Collagen is manufactured using tuna sourced from clean, open seas through an eco-friendly patented process that eliminates chemical treatments such as acid and alkali processing. The product uses low-molecular-weight collagen produced domestically, setting it apart from existing collagen supplements. A key feature of DiNU Core Collagen is that it is made with Korea’s only tuna-derived collagen, developed in collaboration with a domestic university, and that the entire production process—from raw material to finished product—is carried out in Korea. Building on the successful market entry of “DiNU Paraotics,” a patented double-capsule probiotic product, Daehan Nupharm is leveraging its expertise in obesity and wellness to develop differentiated health functional foods that combine unique raw materials and advanced technology.

Daehan Nupharm announced that it has received marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its new gastroesophageal reflux disease (GERD) treatment, “Rapiduo Tab.” As part of its transformation into a research-driven pharmaceutical and biotech company, the firm is focusing on the development of both incremental and innovative new drugs. Rapiduo Tab is one of the company’s key pipeline products and represents a novel combination of rabeprazole (a proton pump inhibitor, PPI) and an antacid.Rabeprazole is chemically unstable in acidic environments and rapidly degrades in gastric acid. To address this, Rapiduo Tab combines rabeprazole with magnesium oxide for the first time, allowing magnesium oxide to neutralize gastric acid and raise intragastric pH, thereby protecting rabeprazole from degradation and enabling rapid absorption. This results in faster acid suppression compared to existing therapies. Rapiduo Tab demonstrated a Tmax of less than one hour after administration, confirming superior acid control versus reference products. It also applies dual-core tablet technology to reduce tablet size and improve patient compliance. Rapiduo Tab 10/350 mg is scheduled for launch in March 2024, while the 20/350 mg high-dose formulation is planned for release in the second half of 2024. Daehan Nupharm continues to expand its incremental drug development efforts across both the gastroenterology and cardiovascular therapeutic areas.

Daehan Nupharm announced that its cumulative sales for the third quarter of 2023 reached KRW 153.6 billion, representing a 3.9% increase year-on-year. Cumulative operating profit came to KRW 18.1 billion, with an operating profit margin of 11.8%. The company is steadily progressing toward its annual sales target of KRW 200 billion and plans to further expand R&D investment to strengthen future growth drivers. Daehan Nupharm intends to focus on incremental drug development for prescription pharmaceuticals, while also enhancing dosing convenience through the development of new formulations for diabetes and obesity treatments. Strong growth in injectable products, one of the company’s core business strengths, continues to drive sales. In particular, wellness injections such as Vitamin C Injection and Luthione Injection are posting sustained growth. Sales of Liporase Injection, which contains hyaluronidase, are expected to exceed KRW 9 billion this year. The company’s health functional food segment is also showing steady growth. Daehan Nupharm plans to launch a differentiated collagen product in December, further diversifying its portfolio.